A Genetic Basis of Susceptibility to Acute Pyelonephritis by Lundstedt, Ann-Charlotte et al.
A Genetic Basis of Susceptibility to Acute Pyelonephritis
Ann-Charlotte Lundstedt
1, Shane McCarthy
2, Mattias C. U. Gustafsson
1, Gabriela Godaly
1, Ulf Jodal
3, Diana Karpman
4, Irene Leijonhufvud
1,
Carin Linde ´n
5, Jeanette Martinell
3, Bryndis Ragnarsdottir
1, Martin Samuelsson
1, Lennart Truedsson
1, Bjo ¨rn Andersson
2, Catharina Svanborg
1*
1Department of Microbiology, Immunology and Glycobiology, Institute of Laboratory Medicine, Lund University, Lund, Sweden, 2Department of Cell
and Molecular Biology, Karolinska Institutet, Stockholm, Sweden, 3Department of Pediatrics, the Queen Silvia Children’s Hospital, Gothenburg
University, Gothenburg, Sweden, 4Department of Pediatrics, Lund University, Lund, Sweden, 5Department of Infectious Diseases, Gothenburg
University, Gothenburg, Sweden
Background. For unknown reasons, urinary tract infections (UTIs) are clustered in certain individuals. Here we propose a novel,
genetically determined cause of susceptibility to acute pyelonephritis, which is the most severe form of UTI. The IL-8 receptor,
CXCR1, was identified as a candidate gene when mIL-8Rh mutant mice developed acute pyelonephritis (APN) with severe
tissue damage. Methods and Findings. We have obtained CXCR1 sequences from two, highly selected APN prone patient
groups, and detected three unique mutations and two known polymorphisms with a genotype frequency of 23% and 25%
compared to 7% in controls (p,0.001 and p,0.0001, respectively). When reflux was excluded, 54% of the patients had CXCR1
sequence variants. The UTI prone children expressed less CXCR1 protein than the pediatric controls (p,0.0001) and two
sequence variants were shown to impair transcription. Conclusions. The results identify a genetic innate immune deficiency,
with a strong link to APN and renal scarring.
Citation: Lundstedt A-C, McCarthy S, Gustafsson MCU, Godaly G, Jodal U, et al (2007) A Genetic Basis of Susceptibility to Acute Pyelonephritis. PLoS
ONE 2(9): e825. doi:10.1371/journal.pone.0000825
INTRODUCTION
The genetic basis of susceptibility to common infectious diseases is
largely not determined, except for one or two classical examples
like malaria and hemoglobin A/E polymorphisms [1,2]. Our
laboratory has for many years been involved in an attempt to
characterize the determinants of susceptibility to acute and chronic
form of urinary tract infection (UTI) but so far, we and others have
failed to identify genetic factors determining disease susceptibility
in man. In an effort to characterize susceptibility mechanisms and
gene(s) associated with particular infections, we have studied UTI
susceptibility in ‘‘knock-out’’ mice with defects in specific loci
[3,4,5]. We have obtained evidence that the deletion of a single
gene encoding the murine IL-8 chemokine receptor homologue
(mIL-8Rh) precipitates the entire syndrome of acute pyelonephritis
(APN) and renal scarring. In view of these findings, we have
investigated whether genetic variability in the human chemokine
receptor gene (CXCR1) might contribute to the disease incidence
in APN-prone individuals.
UTIs are among the most prevalent bacterial infections in man
and remain a significant concern due to their frequency and
associated morbidity and mortality [6,7]. Acute pyelonephritis
(APN) is the most severe and rare form of UTI, and recurrent
APN is clustered in a small group of highly susceptible individuals,
some of whom develop progressive renal scarring and may need
dialysis and transplantation [7,8,9]. There have been many
attempts to identify the host factors, which predispose to UTI,
and especially to APN. Mechanical dysfunctions like vesico-
ureteric reflux increase the access of bacterial to the kidneys, but
uro-dynamic abnormalities alone do not render patients prone to
APN [8,9,10]. The P blood group and secretor state determine the
mucosal repertoire of receptors for P fimbriae and help select the
infecting Escherichia coli strain, but variant receptor expression does
not influence the efficiency of the antibacterial defense [10].
Furthermore, Mendelian primary immuno-deficiencies do not
predispose to UTI in man [11,12] and attempts to relate the HLA
antigen type to UTI have failed [13].
The urinary tract relies on innate immunity to eliminate
clearance and maintain tissue integrity, and single gene defects
have been shown to confer susceptibility in the murine model
[14,15]. The mIL-8Rh chemokine receptor mutant mice develop
acute, septic pyelonephritis with about 50% mortality [4,12,16].
They lack the single chemokine receptor for neutrophil chemo-
attractants and develop an exaggerated acute inflammatory
response, which leads to renal scarring [4,12,16]. Based on the
susceptibility of the mIL-8Rh mutant mice, we performed
a preliminary clinical study of IL-8 receptor expression in APN
prone children [5]. Two human receptors interact with IL-8 and
related chemokines [17,18]. CXCR1 is specific for IL-8 and GCP-
2 while CXCR2 is more promiscuous [19]. We found that the
expression of CXCR1 but not CXCR2 was reduced, suggesting
that variant CXCR1 receptor expression might influence human
APN susceptibility [5]. A recent family study showed a strong
accumulation of APN, further suggesting that APN susceptibility
might be inherited [20].
Here we have identified disease-associated polymorphisms and
mutations in the CXCR1 gene among APN prone patients,
suggesting a novel, genetically determined cause of APN
susceptibility.
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Patients
Sixty patients with APN and recurrent UTI were studied. 24
infants and children were followed from their first episode of APN,
with regular controls at the Department of Pediatrics, Lund
University Hospital for a median of 4.5 years. They were ,1t o
9 years old (median 1.5 years) at the first infection and 1 to
12 years old (median 6 years) at the time of testing (for clinical
data, see Supporting Information Table S1). Seven patients had
recurrent pyelonephritis, 23 had an initial episode of pyelonephri-
tis followed by episodes of acute cystitis (n=7) or asymptomatic
bacteriuria (ABU, n=4). Seven children had a single episode of
APN. On 99mTc-DMSA scintigraphy, 19 of the children had
renal polar uptake defects typical of pyelonephritis, nine children
showed renal scars. All children underwent ultrasound investiga-
tion and voiding cystourethography (VCUG) and vesico-ureteric
reflux (VUR) was detected in 11/24, of which one had structural
abnormalities (double ureters), and one had ureterocele. Hydro-
nephrosis was found in 2/24. The remaining 11 patients had no
structural abnormalities (Table S1).
All but one pediatric patient were Caucasians, and 21 were born
to Swedish parents. The father of P8 was from Slovakia, P13 was
of Polish origin and P14 was adopted from China. Variants 1 and
2 were detected in patients P8, P13 and P14, but the remaining
patients with variants 1 and 2 and those with variants 3, 4 and 5
were born to Swedish parents.
Thirty-six patients were adults with a history of childhood APN,
who participated in a study of febrile UTI in the 1970ies (median
age 4 years) and were followed regularly since then. Between 2002
and 2005, a median of 30 years after the initial UTI episode the
patients were reinvestigated [21]. Samples for CXCR1 analysis in
this study were obtained, the UTI history was recorded and the
kidney status was defined by DMSA scans and Cr51 EDTA
clearance. All adult patients were Caucasians.
Significant bacteriuria was defined by growth of a single strain
(.10
5 cfu/ml) in a mid-stream urine sample, or by any growth in
a supra-pubic bladder aspirate. Pyelonephritis was defined as
a febrile infection ($38.5uC) with significant bacteriuria, C-
reactive protein .20 mg/l and lack of symptoms of other
infections. ABU was defined as .10
5 cfu/ml in three consecutive
urine samples in an asymptomatic individual.
The studies were approved by the Medical Ethics Committees
(IRBs) of the Lund University and the Gothenburg University (LU
236-99, LU 106-02). Informed consent was obtained from all
subjects and/or the parents. Patient information was handled
according to the HIPPA.
Controls
Pediatric controls (n=26) were enrolled when they attended the
Pediatric outpatient clinic or were admitted for elective surgery
and were interviewed to ensure that they had no history of UTI or
other severe infections. There were 26 children (15 boys and 11
girls) aged 1 to 13 years at the time of sampling (median 6 years).
CXCR1 expression was examined in 16 and CXCR1 variants in 26
controls. Adult healthy blood donors (n=200) from the same
geographic area were included as controls to assess the frequency
of CXCR1 sequence variants in the background population. Their
UTI history had not been penetrated. The pediatric controls were
born to Swedish parents.
Genomic DNA Analysis
Genomic DNA was extracted from peripheral blood neutrophils
using proteinase K and phenol-chloroform. Specific primer pairs
were designed according to the published genomic DNA sequence
for CXCR1 (GenBank accession number: L19592). Primers were
chosen based on 39 specificity for the CXCR1 gene (Table S2), in
order to avoid mis-amplification of the CXCR1 pseudo-gene (gi
186372). Patient forward and reverse sequences were base called
and multi-aligned along with control sequences using PolyPhred
[22] and Phrap (http://www.phrap.org) respectively.
Sequencing of the amplicons was in both directions, using
specific nested primers covering 800 bp upstream of the
transcription start to 117 bp downstream of the poly-adenylation
(PolyA) signal of the larger of the two mRNA transcripts [23]. In
total 5119 bps were amplified from each individual DNA (not
including overlaps), resulting in 255.45 kbp for sequence analysis,
comparison and single nucleotide polymorphism (SNP) mining. In
addition, 1261 bp encompassing a 500 bp fragment upstream of
the gene was sequenced to examine possible additional regulatory
elements. The sequences were visualized and manually compared
using Consed [24]. Known SNPs in dbSNP [25] were tagged to
identify novel variants. The CXCR1 promoter (nt 2800 to +98)
was sequenced using the BigDye
TM Terminator Cycle Sequencing
v2.0 Ready Reaction Kit and a fluorescence based automated
cycle sequencer, ABI PRISM
TM 377 (Perkin-Elmer Applied
Biosystems) Data were analyzed using BioEdit (T. Hall, http://
www.mbio.ncsu.edu/BioEdit/bioedit.html). The CXCR1 gene re-
gion (nt 23342 to 22071 and nt 2580 to +4318) was sequenced
on a MegaBACE 1000 using the DYEnamic
TM ET dye
Terminator Kit (Megabace
TM) (Amersham Pharmacia Biotech).
Data were analyzed using Polyphred–Phrap and Consed.
Pyrosequencing
Variants in CXCR1 were identified in a Pyrosequencer PSQ 96
using the PSQ 96 SNP Reagent Kit (Pyrosequencing AB, Uppsala,
Sweden). The PCR amplification primers for variants 1–5, the
nested PCR and pyrosequencing sequencing primers (Table S3)
were designed according to the manufacturer’s instructions
(Pyrosequencing AB; http://www.pyrosequencing.com).
CXCR1 receptor expression
Neutrophils were purified from heparinized whole blood on
a Polymorphprep
TM density gradient (AXIS-SHIELD, PoC AS)
and surface expression of CXCR1 was detected by confocal
microscopy (Bio-Rad Laboratories) and quantified by flow
cytometry (Coulter, 3000 cells/sample) as previously described
[5]. Receptor expression in patient and control samples was
related to an adult standard, run at the same time [5].
Protein extracts and Electrophoretic Mobility Shift
Assay (EMSA)
Nuclear extracts were prepared from the myeloid cell-line HL60,
clone 15, (ATCC No. CRL-1964) [26] with 0.6% NP-40 in the
lysis buffer and protease inhibitors (Complete, Roche) in all buffers
[27], and stored as aliquots at 280uC. Protein concentrations were
measured using the DC Protein Assay kit (Bio-Rad) with bovine
serum albumin as standard. EMSA was performed using the Gel
Shift Assay System (Promega). Double stranded oligonucleotides
encompassing the putative RUNX1 binding site in the CXCR1
intron (common allele 59-CTCTTGTGACCACCACTCAT-39;
SNP1 59-CTCTTGTGACCAGCACTCAT-39) were end-labeled
with [c-
32P]ATP (Amersham Biotech) to similar specific activities.
DNA-protein complexes were separated on 6% polyacrylamide
TBE gels (Invitrogen) and visualized by autoradiography in
a PhosphorImager, STORM 840 (Amersham Pharmacia Biotech).
Unlabeled ds-oligonucleotides at 10- to 100-fold molar excess were
CXCR1 Polymorphisms and UTI
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CACATCTTTAAC-39 as an unspecific competitor, and quanti-
fied in a PhosphorImager, STORM 840 (Amersham Pharmacia
Biotech). The DNA-binding protein was identified using
a RUNX1-specific antibody (AML-1, sc-8563 X) or an irrelevant
antibody control (ATF-2, sc-6233 X) (Santa Cruz Biotech). The
TFSEARCH database was used to predict the transcription
factor binding sites. (http://molsun1.cbrc.aist.go.jp/research/db/
TFSEARCH.html) [28].
Real-time PCR
Total RNA was reverse transcribed using the TaqMan Reverse
TranscriptionReagentskitandrandomhexamersoroligodTprimers
according to the manufacturer’s instructions (Applied Biosystems).
ResidualgenomicDNAwasremovedusingRQ1RNase-freeDNase
(Promega). GAPDH (Assay ID Hs99999905_ml, Applied Biosys-
tems), CXCR1 total (assayID Hs00174146_ml, Applied Biosystems)
andCXCR1large(specifics,seebelow)transcriptswerequantifiedby
real-time PCR using a Corbett Research Rotor-Gene instrument.
The assay was designed using Vector NTI (Informax), CXCR1
forward primer 59-GGTTGTGACAGAGTCAAGGGTGTGT-39
and reverse primer 59-TGTGCCTCAAGAGACTGTTCTAGCA-
39.T h ep r o b e5 9-GGCAGCACCTCC TAAGAAGGCA CCT-39
was 59-end labeled with FAM and 39-end labeled with Black Hole
Quencher 1 (MWG Biotech).
Luciferase reporter assay
We constructed luciferase reporter plasmids by cloning a single
copy of the RUNX1 binding motif containing the wild-type
(pAML1wt-TK-luc) or the SNP1 (pAML1SNP1-TK-luc) allele
upstream of the TK promoter. The plasmids were constructed by
cloning the annealed 59-phosphorylated primer pairs in pGL3-
TK-luc vector cleaved with XhoI and BamHI. For primers see
Table S3.
For the luciferase assay, we cultured A498 cells in RPMI 1640
medium supplemented with 10% fetal bovine serum in 6-well
culture plates at a density of 5610
5 cells per well. The cells were
transiently transfected with 3.5 mg of either constructs and co-
transfected with 0.10 mg of a plasmid encoding AML-1b [27],
(kindly provided by Dr. U. Gullberg, Lund University, Lund,
Sweden) by using Lipofectamine 2000 (Invitrogene). A reporter
construct (3,5 mg) containing the CXCR1 promoter, exon 1, the
intron with a RUNX1 binding motif and exon 2 up to the coding
sequence were transiently transfected into the A498 cells. The cells
were also co-transfected with 0.10 mg of the plasmid encoding
AML-1b and/or with 0.10 mg of a plasmid encoding PU.1 [27],
(kindly provided by Dr. U. Gullberg, Lund University, Lund,
Sweden). The cells were collected 24 h post-transfection and
luciferase activity was measured with the Dual-Luciferase Re-
porter Assay System (Promega).
Statistical Analysis
CXCR1 expression and mRNA levels in pediatric patients and
controls and the luciferase assay data was compared by the Mann-
Whitney U test, two-sided. The CXCR1 genotype and allele
frequency was examined using chi-square Test. The Fishers’ exact
test was used to calculate the total CXCR1 frequency of in patients
with and without VUR compared to pediatric controls. (Graph-
Pad Instat 3 for Macintosh (GraphPad Softwear, Inc.).
RESULTS
The different forms of UTI must be distinguished, to appreciate
differences in disease susceptibility and to enrich for low frequency
genetic factors. The patients in the present study were a subset of
children with APN, which is the most severe but least frequent form
of UTI. The cumulative APN frequency is about four per cent up to
7 years of age, and only about 1/100 to 1/200 of patients
experience recurrent APN after a first APN episode [29,30]. As
a consequence, children with APN and recurrent UTI represent
a highly selected subset of all patients with childhood UTI.
Here, we have examined CXCR1 DNA sequences in two,
independent groups of APN prone individuals. The first group
consisted of prospectively enrolled children (n=24) who were
followed from their first episode of APN, with regular controls at
the Department of Pediatrics, Lund University Hospital. They
were ,1 to 9 years old (median 1.5 years) at the first infection and
1 to 12 years old (median 6 years) at the time of testing (for clinical
data, see Table S1). Pediatric controls of the same age (n=26)
were enrolled when they attended the Lund university hospital for
diagnoses unrelated to infection.
The second patient group was enrolled in a prospective study of
febrile UTI in the 1970ies at a median age of 4 years and was
prospectively followed [21]. The patients were reinvestigated
between 2002 and 2005, a median of 30 years after the initial
APN episode, and samples for CXCR1 sequencing were obtained
from 36 patients, who had a history of APN and recurrent UTI.
Adult healthy blood donors (n=200) were included, to assess the
frequency of CXCR1 sequence variants in the background
population.
CXCR1 sequence variants
The human IL-8 receptor genes CXCR1 and CXCR2 and
a homologous pseudo-gene have been mapped to position 2q35
[31,32]. CXCR1 comprises two exons interrupted by an intron of
1.7 kb and the entire coding sequence is in exon 2 (Fig. 1a). The
CXCR1 promoter (2841 to +21) contains a TATA box equivalent,
GC-rich motifs that may serve as SP-1 and AP-2 sites, and
a GGAA motif serving as a binding site for PU.1, which is
a member of the Ets family of transcription factors. Most of the
promoter activity is determined by sequences from 256 bp to
+50 bp, relative to the transcription start site, with positive
regulatory elements located at 2126 to +50 bp, and negative
regulatory elements located upstream from 2126 to about
2640 bp. The GGAA binding site for PU.1 is adjacent to the
transcription start site at 27t o24 [23,33,34].
Genomic DNA was sequenced using overlapping primers,
covering the entire CXCR1 gene (Fig. 1a, Table S2). The
nucleotides were numbered relative to their distance from the
transcription start site. Five sequence variants were detected in the
intron, the coding region of exon 2 and in the 39 untranslated
region (39UTR) of CXCR1 (Fig. 1a). Variant 1 in the intron was a C
to G nucleotide substitution at position +217 (3943:L19592),
217 bp from the transcription start site and 317 bases upstream of
an ALU element. Variant 2 in exon 2 was a G to C substitution at
position +2608 (6334:L19592), resulting in a non-synonymous
amino acid change from Serine (Ser) to Threonine (Thr). In the
39UTR, a C to T transition (variant 3) was detected at position
+3081 (6807:L19592) and a G to A transition (variant 4) at
position +3082 (6808:L19592). Variant 5 was a G to A transition
at position +3665 (7391:L19592) between the Poly(A) signal and
the Poly(A) sites of the short mRNA (Fig. 1a).
Difference in SNP frequency between patients and
controls
Full-length CXCR1 DNA sequences were obtained from 12
pediatric patients, 35 adult patients with childhood APN and 12
CXCR1 Polymorphisms and UTI
PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e825Figure 1. Sequence variation in the human CXCR1 locus. a, Genomic organization of CXCR1 and positions of genetic variants (Variants 1–5) in the
intron, the coding sequence (CDS) and in the 39untranslation region (39UTR). b, Comparison of the human CXCR1 gene with its rat ortholog (Il8ra).
BLAST homologies indicating strongly conserved regions are shown by the lines connecting the genes. The five CXCR1 variants identified in the
patients are all located in or near strongly conserved regions as indicated. The rat was selected, as the human CXCR1 gene does not have an ortholog
in the mouse where the equivalent of the human CXCR2 (mIL-8Rh or Il8rb) gene carries out the same function. c, Predicted effects of CXCR1 variants
on putative transcription factor binding motifs based on a TRANSFAC search. The transcription factors and % score match of the mutant alleles are
shown. d, Variant 1 (enlarged, bold) potentially disrupts the RUNX1 binding motif.
doi:10.1371/journal.pone.0000825.g001
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pediatric patients, 1 adult patient, 14 pediatric controls and DNA
from 200 adult healthy blood donors was screened for the
identified CXCR1 variants, using pyrosequencing with primers
specific for each variant.
Single base changes in CXCR1 were associated with APN
susceptibility in the pediatric population. Sequence variants were
detected in 9/24 (37.5%) of the APN prone children, but only in
1/26 (4%) of the pediatric controls (Table 1). Six patients were
heterozygous for variants 1 and 2, which were present on 6/48
chromosomes, resulting in minor allele frequencies of 13%. One
control child was homozygous for variant 1, resulting in a minor
allele frequency of 4%, (2/52 chromosomes). Sequencing of parent
DNA showed that variants 1 and 2 were linked. Variants 3, 4 and
5 occurred as heterozygous mutations in one patient each and
were unique for the pediatric patients.
In the adults, CXCR1 variants 1 and 2 were detected in 9/36
(25%) and 10/36 (28%), respectively. One patient was homozy-
gous for variant 2, resulting in a minor allele frequency of 15% for
variant 2 and 13% for variant 1 in this group. Variants 1 and 2
were detected by pyrosequencing in 16/200 (8%) of controls on
16/400 chromosomes, resulting in a minor allele frequency of 4%
(Table 1, p=0.0056 for variant 1 and p=0.0018 for variant 2
compared to the adult patients and p=0.0185 compared to the
children with APN, Fischer’s exact test, two-sided). The results
showed that single base changes in CXCR1 are associated with
susceptibility to APN also in adults, thus confirming the disease
association of these variants (Table 2, Table 3).
Putative effects on CXCR1 expression
Variants 1, 3 and 4 were located to sequences with high homology
to transcription factor binding motifs, identified by TRANSFAC
(Fig. 1c). Variant 1 (217C/G) was in a putative binding site for the
runt-related transcription factor 1 (RUNX1, also called AML1)
(Fig. 1d), which is required for expression from a number of cell
specific enhancers and promoters [35,36]. The cyclic-AMP-
dependent transcription factor ATF-2 (CRE-BP1, compatible
transcription factor motif of the common allele) was lost in both
the variant 3 (+3081T) and variant 4 (+3082A) -bearing alleles but
they retained the potential v-Myb DNA-binding sites from the
common allele (Fig. 1c).
The reduction in RUNX1 binding to the variant 1 sequence
was confirmed by electrophoretic mobility shift assay (EMSA)
(Fig. 2). Nuclear extracts from the HL60 cell-line were used. HL60
cells are promyelocytic leukemic cells and a significant percentage
of the cultured cells (10–12%) differentiate spontaneously into
mature neutrophils [37]. The HL60 cells are thus neutrophil like
and are an accepted model to study neutrophil cells. In addition,
they express high amounts of the transcription factor AML1.
Mature neutrophils, in contrast, are end stage cells, which are
difficult to maintain in vitro for more than a few hours and which
are difficult to transfect. Furthermore, the concentration of
proteolytic enzymes is very high and it is difficult to isolate intact
nuclear proteins.
HL60 cell nuclear extracts were incubated with oligonucleotide
probes encompassing the putative RUNX1 binding site, and
complex formation was detected by gel electrophoresis. There was
a significant decrease in RUNX1 binding to the mutated sequence
compared to the common allele (wt-probe) (Fig. 2a, lanes 2 and 4).
The specificity was confirmed by competition with cold common
allele probe at 100 fold molar excess, but an unrelated probe had
Table 1. Number of individuals with CXCR1 sequence variants
......................................................................
Variant
sequences
Consensus
sequence Total
n( % ) n( % ) n
APN in childhood 19 (32) 41 (68) 60
-Lund population 9 (37.5) 15 (62.5) 24
-Gothenburg population 10 (28) 26 (72) 36
Controls 17 (8) 209 (92) 226
-Pediatric 1 (4) 25 (96) 26
-Adult 16 (8) 184 (92) 200
APN=Acute pyelonephritis. Lund population=Paediatric patients followed
from their first infection. Gothenburg=patients with APN in childhood during
the 1970ies who were re-examined for this study.
doi:10.1371/journal.pone.0000825.t001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Table 2. Frequency of CXCR1 sequence variants 1 and 2
..................................................................................................................................................
Genotype frequency, variant 1 (+217)
# Genotype frequency, variant 2 (+2608)
##
CC (%) Cg (%) gg (%) p
a) GG (%) Gc (%) cc (%) p
b)
APN total n=60 45 (75) 14 (23) 1 (2) 0.0007 44 (73) 15 (25) 1 (2) ,0.0001
Control total n=226 209 (92.5) 16 (7) 1 (0.5) 210 (93) 16 (7) 0
APN=Acute pyelonephritis; n=number of individuals;
# nucleotide at position +217 in the intron.
## nucleotide at position +2608 in the coding sequence.
a), b)=Chi-
square Test, total number of APN prone patients versus total number of controls.
doi:10.1371/journal.pone.0000825.t002
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Table 3. Allele frequency of CXCR1 sequence variants 1 and 2
..................................................................................................................................................
Allele frequency (+217)
# Allele frequency (+2608)
##
C( % ) g( % ) p
a) G (%) c (%) p
b)
APN prone, total n=60 N=120 104 (87) 16 (13) 0.0007 103 (86) 17 (14) ,0.0001
Control total n=226 N=452 434 (96) 18 (4) 436 (96) 16 (4)
APN=Acute pyelonephritis; n=number of individuals; N=number of alleles;
# nucleotide at position, +217 in the intron.
## nucleotide at position +2608 in the coding
sequence.
a), b) Fischer’s Exact Test, total number of APN prone patients versus total number of controls.
doi:10.1371/journal.pone.0000825.t003
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PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e825Figure 2. Effects of CXCR1 sequence variants on transcription. a, EMSA, showing the binding to the putative RUNX1 oligonucleotides of proteins in
a HL60 cell nuclear extract. Binding (arrow) was stronger to the wild type (lane 2) than to the variant 1 oligonucleotide (lane 4). Lanes 1 and 3 are
probes without proteins. b, Competitive inhibition of binding by cold intact probe (100-fold excess, lane 3), but not by unspecific probe (1006excess,
lane 4). A super-shifted band, indicated by the arrow, was obtained with anti-RUNX1 (lane 5) but not with control antibody (anti ATF-2) (lane 6).
Hatched lines indicate removed excess lanes. c, Inhibition of specific wild-type binding by unlabeled wt probe (106–1006, lanes 2–5) and reduced
efficiency of competition with unlabelled SNP1 probe (106–1006, lane 6–9). d, The inhibition of the DNA-protein interaction in Panel c was
quantified in a Phosphor Imager. e, Effect of SNP1 on RUNX1-dependent transcriptional transactivation. Allelic differences in relative luciferase activity
in pAML1 (wt/SNP1)-TK-luc transfected A498 cells with or without co-transfection with an AML-1b expression vector. Data show the mean 6 SEMs of
three separate experiments done in duplicate. *P=0.0104 and **P=0.1199 by the Mann-Whitney U test, two-tailed. f, RUNX1 and PU.1 interacts with
the CXCR1 promoter in transfected A498 cells. The CXCR1 promoter activity was quantified using luciferase. The signal was enhanced by co-
transfection with the AML1b (RUNX1) and PU.1 expression plasmids.
doi:10.1371/journal.pone.0000825.g002
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identified as RUNX1 by specific antibody (Fig. 2b, lane 5) in
a super-shift assay and the specificity was confirmed by
competitive inhibition with unlabelled wt-probe (Fig. 2c, lane 2–
5) or SNP1 (variant 1) probe (Fig. 2c, lane 6–9). Variant 1 was
a less efficient inhibitor than the common allele (Fig. 2d).
To examine the effect of variant 1 on RUNX1 transcriptional
transactivation, we constructed a luciferase reporter carrying the
putative RUNX1 binding motif with the variant 1 (pAML1SNP1-
TK-luc) or the wild type allele (pAML1wt-TK-luc) and the
luciferase activity was used as a read out of RUNX1-dependent
transcription. To control transcription, we selected human kidney
epithelial cells (A498), which lack the RUNX1 transcription factor.
RUNX1 dependent transcription was artificially induced, by co-
transfecting the cells with an AML-1b expression vector and as
a result, RUNX1 dependent transcription was enhanced (Fig. 2e).
In this RUNX1 dependent assay, the luciferase activity from the
mutant allele was reduced compared to the wild type allele, thus
supporting the hypothesis that variant 1 reduces CXCR1
transcription. Further evidence of RUNX1 involvement in CXCR1
transcription was obtained by co-transfection of A498 cells with
a CXCR1 promoter reporter plasmid and vectors encoding
RUNX1 and PU.1. The promoter was fully functional, and both
RUNX1 and PU.1 were required to enhance luciferase activity
(Fig. 2f).
Aberrant CXCR1 mRNA processing associated with
variant 5
CXCR1 has two alternative poly(A) sites and a long and a short
transcript are formed [23]. Variant 5 caused a 39 G to A transition
at position +3665, between the first poly(A) signal and the poly(A)
sites (Fig. 1a, b). A similar polymorphism in the prothrombin gene
has been shown to increase the efficiency of mRNA 39-processing
[38,39]. If variant 5 had a similar effect, the levels of the long
CXCR1 transcripts would be reduced. The long and total
CXCR1 transcripts were quantified by RT-PCR using cDNA
reverse transcribed with random hexamers or oligo dT primers.
The mRNAs from the patient carrying variant 5 and the mother
with the same mutation contained reduced levels of the CXCR1
large transcript compared to the control, thus confirming the
predicted effect of variant 5, suggesting that this mutation might
create a more efficient cleavage site and thus reduce the amount of
large CXCR1 mRNA (data not shown).
Vesico-ureteric reflux
Reflux is known to predispose to acute pyelonephritis and renal
scarring. The relative contribution to APN susceptibility of vesico-
ureteric reflux (VUR) and CXCR1 sequence variation was
therefore examined in the APN prone children, where 11/24
had VUR and two had structural abnormalities (ureterocele and
double ureters) (Table 4). The patients without VUR had a higher
frequency of CXCR1 sequence variants (7/13, 54%) than the
children with VUR (2/11, 18%, Table 4). The group without
VUR was significantly different from the controls (p=0.0007) but
the patients with VUR were not (n.s., Table 4). The results suggest
that CXCR1 sequence variation and VUR are independent risk
factors in APN-prone patients.
Low CXCR1 surface expression in APN-prone
children
We obtained peripheral blood neutrophils during an infection free
interval or while the patient received antibiotic prophylaxis. By
confocal microscopy (Fig. 3a) we observed that the surface staining
for CXCR1 was markedly reduced in the patients compared to the
controls. The difference in CXCR1 expression was quantified by
flow cytometry analysis of 23 patient and 16 control samples
(Fig. 3b). The patient CXCR1 expression showed a mean of
21,44, range 26.52–(1.04) compared to the standard while the
controls showed a mean of 0.28, range 20.73–(2.15), (p,0.0001
for the group-wise analysis, Mann-Whitney U test, two-tailed). The
results confirmed and extended data on CXCR1 expression from
the preliminary study by Frendeus et al. [5]. Patients 1–12 in that
study had CXCR1 levels of 21.33, range 26.52–(1.04). The
newly recruited patients 13–21 and 23–24 in this study expressed
a mean of 21.57, range 22.76–(0.63) compared to the standard.
DISCUSSION
A subset of all children with UTI are APN prone, and risk to
develop recurrent infections and kidney damage [29]. There have
been many attempts to identify the host factors, which predispose
them to infection. Reflux, blood groups, social and environmental
variables have been discussed but molecular markers have not
been identified until mIL-8Rh mutant mice were shown to
develop APN with bacteremia and renal scarring [6,8,9,10]. Here
we show that variation in the human IL-8 receptor gene may
influence APN susceptibility and propose a mechanism how the
variant alleles may suppress innate immunity in the urinary tract.
Five CXCR1 sequence variants were detected in carefully selected
patients with APN. Three new 39 mutations were unique to the
patients and two known variants were more common in patients
than in controls, supporting a disease association. Variant 1
reduced the efficiency of RUNX1 dependent transcription and
another three variants were located to transcription factor binding
sites. As expected, CXCR1 expression was markedly reduced in
the APN prone children compared to controls. The results suggest
that CXCR1 variants may render individuals UTI-prone by
lowering CXCR1 expression and by incapacitating the neutro-
phil-dependent host defense against UTI.
Innate immunity controls the resistance to UTI and neutrophils
are needed for bacterial clearance from infected tissues. The
chemokine receptor deficiency in mIL-8Rh knock out mice
incapacitates neutrophils by delaying their migration into the
kidneys and their exit from the tissues across the mucosal barrier.
Table 4. CXCR1 sequence variants related to reflux
......................................................................
Number (%) of individuals with variants
Var. 1 Var. 2 Var.3 Var.4 Var.5 Total
+
APN prone children
without VUR
4 (31)* 4 (31)** 1 (8) 1 (8) 1 (8) 7 (54)
?
APN prone children
with VUR
2 (18)
{ 2 (18)
{ 0002 ( 1 8 )
Pediatric controls 1 (4) 0 0001 ( 4 )
The frequency of variants was significantly higher in APN prone patients
without VUR than in paediatric controls.
* p=0.0345 for variant 1 in patients without VUR compared to pediatric
controls
** p=0.0087 for variant 2 in patients without VUR compared to pediatric
controls
{p=0.2053 for variant 1 in patients with VUR compared to pediatric controls
{p=0.0826 for variant 2 in patients with VUR compared to pediatric controls
?p=0.0007 for total variants in patients without VUR compared to pediatric
controls
Fischers exact test, two sided;
+=number of individuals with variant CXCR1 sequences
doi:10.1371/journal.pone.0000825.t004
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PLoS ONE | www.plosone.org 7 September 2007 | Issue 9 | e825In addition, the receptor is needed for neutrophil activation and
phagocytosis and killing of bacteria is impaired in knock out mice.
As a result, bacteria persist in the kidneys, and the trapped
neutrophils destroy the tissues [4,12,16]. Similar conclusions were
drawn in a recent study, where polymorphisms in the ICAM-1
gene were shown to protect against renal scarring following UTI
by decreasing the number of neutrophils and thereby the
inflammatory host response [40]. ICAM-1 is expressed on
endothelial cells as well as on kidney and bladder epithelial cells
and acts as a counter-receptor for Mac-1 [41]. ICAM-1 expression
is increased on the cytokine-activated endothelium [42] and on
infected epithelium [43] and is involved in the endothelial and
epithelial transmigration of neutrophils [43,44]. These observa-
tions illustrate the delicate balance between the protective and
destructive aspects of the neutrophil-dependent defense against
UTI.
Figure 3. Low CXCR1 expression on neutrophils from pyelonephritis prone children compared to pediatric controls. a, Confocal microscopy
images of individual samples from eight patient and controls, using a monoclonal anti-human CXCR1 primary and a FITC conjugated, anti-mouse
secondary antibody. b, Quantification by flow cytometry of CXCR1 expression in patients (white peaks) and controls (black peaks).
doi:10.1371/journal.pone.0000825.g003
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PLoS ONE | www.plosone.org 8 September 2007 | Issue 9 | e825The UTI associated CXCR1 variant 1 was shown to reduce
RUNX1 binding to the putative intronic binding site. Further-
more, transfection experiments showed that transcription of the
mutant allele is reduced, suggesting that variant 1 reduces CXCR1
transcription. RUNX1 activates transcription through protein-
protein interactions with the Ets family of transcription factors,
including PU.1, which is a regulator of CXCR1 expression
[34,36]. Neutrophils from PU.1-null mice fail to terminally
differentiate and their neutrophils fail to respond to CXCL8,
indicating that functional receptors are not expressed when this
transcription factor is absent [45]. The importance of PU.1 for
CXCR1 transcription was supported by our in vitro transfection
studies showing an interaction between transcription factors
AML1b (RUNX1) and PU.1 promoted transcription in a luciferase
reporter assay. Reduced RUNX1 binding caused by intronic SNPs
has been proposed to cause aberrant regulation of PDCD1 (the
programmed cell death 1 gene) in patients with systemic lupus
erythematosus [46], and of SLC22A4 in patients with rheumatoid
arthritis [47,48]. In addition, increased susceptibility to psoriasis
was associated with a loss of inter-genic RUNX1 binding [49].
The two additional 39variants (3 and 4) were also proposed to
influence transcription, based on TRANSFAC searches, which
identified putative transcription factor binding sites. Variant 5 was
associated with reduced levels of the large CXCR1 transcript,
suggesting that this mutation might create a more efficient
cleavage site and thus reduce the amount of large CXCR1
mRNA. A similar mutation was shown to create a more efficient
mRNA cleavage site in the pro-thrombin gene where more
efficient processing of the transcript leads to higher pro-thrombin
levels and a higher risk of thrombosis [50]. In addition, there were
several patients with low CXCR1 expression but without variation
in the CXCR1 gene. Thus, even if the frequency of patients with
single base changes was high, there must be additional
mechanisms, which control CXCR1 expression, and which may
be polymorphic in this patient group.
Longitudinal clinical studies must be performed, to reliably
identify those patients, who are susceptible to recurrent APN. Such
protocols were used in the present study, in two separate
geographic sites, resulting in two well-defined, APN-prone patient
populations. We found an increased frequency of CXCR1 sequence
variants in both groups. The pediatric group had been followed
from the first known febrile UTI episode by our clinical team and
the adults were followed regularly from their first febrile UTI
episode for a median of 30 years. The need for stringent clinical
definitions is illustrated by a recent report, which failed to show
a significant increase in variant 2 in patients with DMSA proven
kidney infections [51]. In a second study, low CXCR1 expression
was detected in 3/9 patients with childhood APN and two had
SNPs in exon 2, but the numbers were small and no conclusions
were drawn [52]. The stringent clinical follow up and large
number of APN prone patients probably explains the high
frequency of CXCR1 variants and of reduced CXCR1 expression.
On the other hand, the complicated clinical procedures illustrate
the need for markers, which identify the risk patients already in
connection with their first UTI episode. If this were possible,
proper therapeutic interventions might be made and invasive
diagnostic procedures restricted to patients at high risk, while those
of lower risk might be spared. We are hopeful that the results of
this study will be useful and that they might stimulate attempts to
identify susceptible patients who might benefit from more intense
diagnostic surveillance and therapeutic intervention.
SUPPORTING INFORMATION
Table S1 APN prone patients. Clinical data of the APN-prone
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Found at: doi:10.1371/journal.pone.0000825.s001 (0.05 MB
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